Drug intelligence / Profile preview

LY4060874

Development stage: Phase 1
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Intravenous, Subcutaneous

Overview

LY4060874 is an investigational small molecule drug developed by Eli Lilly and Company. As of early 2025, it is classified as a new molecular entity with an undefined mechanism of action. The drug is currently in preclinical and early clinical development, with a Phase 1 trial underway to evaluate its safety, tolerability, and pharmacokinetics in healthy participants. The specific therapeutic indication for LY4060874 has not been publicly disclosed[1][2][3][4].

Beyond the preview

Go deeper on LY4060874.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY4060874.

Explore the full profile